Targets for CAR Therapy in Multiple Myeloma.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Multiple myeloma (MM) is a complex B-cell malignancy characterized by high recurrence and drug resistance.
• Current standard therapies have limited efficacy, driving the need for novel treatment approaches.
• Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for relapsed and refractory MM.

Purpose of the Study:

• To review and analyze CAR T-cell therapy targets for multiple myeloma.
• To evaluate the biological properties, expression patterns, and clinical development of CAR cell products.
• To explore strategies for overcoming challenges such as antigenic escape in CAR T-cell therapy for MM.

Main Methods:

• Comprehensive literature review of CAR T-cell therapy targets in MM.
• Analysis of biological characteristics and clinical data for various CAR constructs.
• Evaluation of advanced approaches like multi-specific CARs and safety systems.

Main Results:

• Identified and analyzed numerous CAR T-cell targets for MM, including BCMA, GPRC5D, FcRH5, SLAMF7, CD38, and others.
• Highlighted the importance of target selectivity, stable expression, and biological relevance.
• Discussed strategies to mitigate antigenic escape, such as multi-specific CARs and controlled activation.

Conclusions:

• The rational selection of targets and innovative bioengineering are critical for effective CAR T-cell therapy in MM.
• Integrating molecular target insights with advanced engineering solutions will improve efficacy, durability, and safety.
• CAR T-cell therapy holds significant potential for improving outcomes in relapsed and refractory multiple myeloma.